
## Zarife Sahenk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8605158/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dystrophin Immunity in Duchenne's Muscular Dystrophy. New England Journal of Medicine, 2010, 363, 1429-1437.	27.0	546
2	Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy. New England Journal of Medicine, 1995, 333, 832-838.	27.0	489
3	Gentamicinâ€induced readthrough of stop codons in duchenne muscular dystrophy. Annals of Neurology, 2010, 67, 771-780.	5.3	238
4	Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4318-4322.	7.1	235
5	Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy. JAMA Neurology, 2020, 77, 1122.	9.0	226
6	Sustained alphaâ€sarcoglycan gene expression after gene transfer in limbâ€girdle muscular dystrophy, type 2D. Annals of Neurology, 2010, 68, 629-638.	5.3	214
7	A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy. Molecular Therapy, 2015, 23, 192-201.	8.2	193
8	Eteplirsen treatment for Duchenne muscular dystrophy. Neurology, 2018, 90, e2146-e2154.	1.1	175
9	Studies on the pathogenesis of vincristine-induced neuropathy. Muscle and Nerve, 1987, 10, 80-84.	2.2	105
10	Effects of PMP22 duplication and deletions on the axonal cytoskeleton. Annals of Neurology, 1999, 45, 16-24.	5.3	93
11	Defective membrane fusion and repair in <i>Anoctamin5</i> -deficient muscular dystrophy. Human Molecular Genetics, 2016, 25, 1900-1911.	2.9	88
12	AAV1.NT-3 Gene Therapy for Charcot–Marie–Tooth Neuropathy. Molecular Therapy, 2014, 22, 511-521.	8.2	86
13	Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Molecular Therapy, 2017, 25, 870-879.	8.2	84
14	Overexpression of <i>Galgt2</i> in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice. American Journal of Physiology - Cell Physiology, 2009, 296, C476-C488.	4.6	78
15	AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models. Annals of Clinical and Translational Neurology, 2015, 2, 256-270.	3.7	78
16	Abnormalities in the axonal cytoskeleton induced by a connexin32 mutation in nerve xenografts. , 1998, 51, 174-184.		67
17	PUMILIO hyperactivity drives premature aging of Norad-deficient mice. ELife, 2019, 8, .	6.0	65
18	Vascular Delivery of rAAVrh74.MCK.GALGT2 to the Gastrocnemius Muscle of the Rhesus Macaque Stimulates the Expression of Dystrophin and Laminin α2 Surrogates. Molecular Therapy, 2014, 22, 713-724.	8.2	61

2

ZARIFE SAHENK

#	Article	lF	CITATIONS
19	Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. Medicine (United States), 2019, 98, e15858.	1.0	61
20	Axoplasmic transport in zinc pyridinethione neuropathy: Evidence for an abnormality in distal turn-around. Brain Research, 1980, 186, 343-353.	2.2	57
21	Axonal tubulin and microtubules: Morphologic evidence for stable regions on axonal microtubules. Cytoskeleton, 1987, 8, 155-164.	4.4	55
22	Pathogenesis of X-Linked Charcot-Marie-Tooth Disease: Differential Effects of Two Mutations in Connexin 32. Journal of Neuroscience, 2003, 23, 10548-10558.	3.6	53
23	Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model. Human Molecular Genetics, 2013, 22, 4929-4937.	2.9	53
24	Update on the Treatment of Duchenne Muscular Dystrophy. Current Neurology and Neuroscience Reports, 2013, 13, 332.	4.2	52
25	Ultrastructural Study of Zinc Pyridinethione-Induced Peripheral Neuropathy. Journal of Neuropathology and Experimental Neurology, 1979, 38, 532-550.	1.7	45
26	Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. Molecular Therapy - Methods and Clinical Development, 2018, 8, 121-130.	4.1	44
27	A novel <i>PMP22</i> point mutation causing HNPP phenotype. Neurology, 1998, 51, 702-707.	1.1	41
28	AAV1.NT-3 gene therapy increases muscle fiber diameter through activation of mTOR pathway and metabolic remodeling in a CMT mouse model. Gene Therapy, 2018, 25, 129-138.	4.5	40
29	Abnormal Schwann Cell-Axon Interactions in CMT Neuropathies: The Effects of Mutant Schwann Cells on the Axonal Cytoskeleton and Regeneration-Associated Myelination. Annals of the New York Academy of Sciences, 1999, 883, 415-426.	3.8	37
30	Mutant HSPB1 overexpression in neurons is sufficient to cause age-related motor neuronopathy in mice. Neurobiology of Disease, 2012, 47, 163-173.	4.4	35
31	Fate of Schwann Cells in CMT1A and HNPP: Evidence for Apoptosis. Journal of Neuropathology and Experimental Neurology, 1998, 57, 635-642.	1.7	34
32	Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy. Journal of Neuromuscular Diseases, 2015, 2, 185-192.	2.6	34
33	Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion. Human Gene Therapy, 2019, 30, 794-801.	2.7	34
34	TrkB and TrkC agonist antibodies improve function, electrophysiologic and pathologic features in TremblerJ mice. Experimental Neurology, 2010, 224, 495-506.	4.1	31
35	Impaired regeneration in calpain-3 null muscle is associated with perturbations in mTORC1 signaling and defective mitochondrial biogenesis. Skeletal Muscle, 2017, 7, 27.	4.2	29
36	Neurotrophin-3 deficient Schwann cells impair nerve regeneration. Experimental Neurology, 2008, 212, 552-556.	4.1	26

ZARIFE SAHENK

#	Article	IF	CITATIONS
37	Gene delivery to spinal motor neurons. Brain Research, 1993, 606, 126-129.	2.2	25
38	AAV1.NT-3 gene therapy for X-linked Charcot–Marie–Tooth neuropathy type 1. Gene Therapy, 2022, 29, 127-137.	4.5	22
39	Unmet needs and evolving treatment for limb girdle muscular dystrophies. Neurodegenerative Disease Management, 2021, 11, 411-429.	2.2	22
40	Impaired regeneration in LGMD2A supported by increased PAX7â€positive satellite cell content and muscleâ€specific microrna dysregulation. Muscle and Nerve, 2013, 47, 731-739.	2.2	21
41	Gene therapy to promote regeneration in Charcot-Marie-Tooth disease. Brain Research, 2020, 1727, 146533.	2.2	21
42	Pathogenesis of Autosomal Dominant Hereditary Spastic Paraplegia (SPG6) Revealed by a Rat Model. Journal of Neuropathology and Experimental Neurology, 2013, 72, 1016-1028.	1.7	17
43	Evidence for impaired axonal regeneration in PMP22 duplication: studies in nerve xenografts. Journal of the Peripheral Nervous System, 2003, 8, 116-127.	3.1	16
44	AAV1.NT-3 gene therapy in a CMT2D model: phenotypic improvements in <i>GarsP278KY/+</i> mice. Brain Communications, 2021, 3, fcab252.	3.3	15
45	The Muscular Dystrophies: Distinct Pathogenic Mechanisms Invite Novel Therapeutic Approaches. Current Rheumatology Reports, 2011, 13, 199-207.	4.7	14
46	Clinical trials of exon skipping in Duchenne muscular dystrophy. Expert Opinion on Orphan Drugs, 2017, 5, 683-690.	0.8	14
47	Neurotrophins and Peripheral Neuropathies. Brain Pathology, 2006, 16, 311-319.	4.1	13
48	VIP-expressing Dendritic Cells Protect Against Spontaneous Autoimmune Peripheral Polyneuropathy. Molecular Therapy, 2014, 22, 1353-1363.	8.2	13
49	Alterations in slow transport kinetics induced by estramustine phosphate, an agent binding to microtubule-associated proteins. Journal of Neuroscience Research, 1992, 32, 481-493.	2.9	12
50	A novel p.T139M mutation in HSPB1 highlighting the phenotypic spectrum in a family. Brain and Behavior, 2017, 7, e00774.	2.2	12
51	Efficacy of exogenous pyruvate in Trembler <sup>J</sup> mouse model of Charcotâ€Marieâ€Tooth neuropathy. Brain and Behavior, 2018, 8, e01118.	2.2	12
52	A slowly progressive form of limbâ€girdle muscular dystrophy type 2C associated with founder mutation in the <i>SGCG</i> gene in Puerto Rican Hispanics. Molecular Genetics & Genomic Medicine, 2015, 3, 92-98.	1.2	10
53	A Novel De Novo Heterozygous SCN4a Mutation Causing Congenital Myopathy, Myotonia and Multiple Congenital Anomalies. Journal of Neuromuscular Diseases, 2019, 6, 467-473.	2.6	9
54	Systemic delivery of AAVrh74.tMCK.hCAPN3 rescues the phenotype in a mouse model for LGMD2A/R1. Molecular Therapy - Methods and Clinical Development, 2021, 22, 401-414.	4.1	9

ZARIFE SAHENK

#	Article	IF	CITATIONS
55	Alterations in Nodes of Ranvier and Schmidt-Lanterman Incisures in Charcot-Marie-Tooth Neuropathies. Annals of the New York Academy of Sciences, 1999, 883, 508-512.	3.8	7
56	Pilot Clinical Trial of NT-3 in CMT1A Patients. Progress in Neurotherapeutics and Neuropsychopharmacology, 2007, 2, 97-108.	0.0	7
57	Intracellular Processing and Toxicity of the Truncated Androgen Receptor: Nuclear Congophilia-Associated Cell Death. Journal of Neuropathology and Experimental Neurology, 2000, 59, 652-663.	1.7	1
58	Novel single base polymorphisms and rare sequence variants in the laminin ?2-chain coding region detected by RNA/SSCP analysis. Human Mutation, 1999, 13, 174-174.	2.5	0
59	Autoâ€antibodies Targeting Components of Sarcolemma Repair Represent a Pathogenic Mechanism in Idiopathic Immune Myopathies. FASEB Journal, 2019, 33, 701.2.	0.5	0